David Hutton

IBI324 is a potential first-in-class ophthalmic recombinant human anti-VEGF-A and anti-Ang-2 bispecific antibody.

Trial results demonstrated statistically significant improvement in the prespecified primary endpoint in BCVA at 13 months in the PBM treatment group over the sham-treatment group.

Research to Prevent Blindness will launch the RPB/David L. Epstein Career Advancement Award in Glaucoma Research, sponsored by Aerie Pharmaceuticals.

The nonprofit has continually reached for new heights in the fight against avoidable blindness.

Review treatment options for both early and late complications of cataract surgery.

VUITY, developed by Allergan, is the first and only FDA-approved eye drop to treat presbyopia